Skip to main content
SearchLoginLogin or Signup

Reviews of "Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia"

Reviewers: Natasha Strydom (UCSF) | πŸ“˜πŸ“˜πŸ“˜πŸ“˜πŸ“˜ β€’ Tadamitsu Kishimoto, Sujin Kang (Osaka University) | πŸ“˜πŸ“˜πŸ“˜πŸ“˜πŸ“˜ β€’ Imran Khan(UC Davis) | πŸ“˜πŸ“˜πŸ“˜πŸ“˜πŸ“˜

Published onOct 16, 2020
Reviews of "Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia"
key-enterThis Pub is a Review of
Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia
Description

BACKGROUND COVID-19 is associated with immune dysregulation and hyperinflammation. Tocilizumab is an anti-interleukin-6 receptor antibody. METHODS Patients hospitalized with severe COVID-19 pneumonia receiving standard care were randomized (2:1) to double-blinded intravenous tocilizumab 8 mg/kg or placebo. The primary outcome measure was clinical status on a 7-category ordinal scale at day 28 (1, discharged/ready for discharge; 7, death). RESULTS Overall, 452 patients were randomized; the modified-intention-to-treat population included 294 tocilizumab-treated and 144 placebo-treated patients. Clinical status at day 28 was not statistically significantly improved for tocilizumab versus placebo (P=0.36). Median (95% CI) ordinal scale values at day 28: 1.0 (1.0 to 1.0) for tocilizumab and 2.0 (1.0 to 4.0) for placebo (odds ratio, 1.19 [0.81 to 1.76]). There was no difference in mortality at day 28 between tocilizumab (19.7%) and placebo (19.4%) (difference, 0.3% [95% CI, -7.6 to 8.2]; nominal P=0.94). Median time to hospital discharge was 8 days shorter with tocilizumab than placebo (20.0 and 28.0, respectively; nominal P=0.037; hazard ratio 1.35 [95% CI 1.02 to 1.79]). Median duration of ICU stay was 5.8 days shorter with tocilizumab than placebo (9.8 and 15.5, respectively; nominal P=0.045). In the safety population, serious adverse events occurred in 34.9% of 295 patients in the tocilizumab arm and 38.5% of 143 in the placebo arm. CONCLUSIONS In this randomized placebo-controlled trial in hospitalized COVID-19 pneumonia patients, tocilizumab did not improve clinical status or mortality. Potential benefits in time to hospital discharge and duration of ICU stay are being investigated in ongoing clinical trials.

To read the original manuscript, click the link above.

Summary of Reviews: An anti-interleukin-6 antibody, tocilizumab, was found to have no significant differences in mortality or clinical outcomes at day 28, but shorter median time to hospital discharge, compared with placebo in a rigorously conducted randomized control trial.

Reviewer 1 (Natasha Strydom) | πŸ“˜πŸ“˜πŸ“˜πŸ“˜πŸ“˜

Reviewer 2 (Tadamitsu Kishimoto,Β Sujin Kang) | πŸ“˜πŸ“˜πŸ“˜πŸ“˜πŸ“˜

Reviewer 3 (Imran Khan) | πŸ“˜πŸ“˜πŸ“˜πŸ“˜πŸ“˜

RR:C19 Strength of Evidence Scale Key

πŸ“• ◻️◻️◻️◻️ = Misleading

πŸ“™πŸ“™ ◻️◻️◻️ = Not Informative

πŸ“’πŸ“’πŸ“’ ◻️◻️ = Potentially Informative

πŸ“—πŸ“—πŸ“—πŸ“—β—»οΈ = Reliable

πŸ“˜πŸ“˜πŸ“˜πŸ“˜πŸ“˜ = Strong

To read the reviews, click the links below.

Comments
2
?
ming jie:

As Game Vault involves betting and understanding odds, it can aid in enhancing financial literacy. Players learn to manage risks, make informed decisions, and grasp the concept of probability. Click here to delve into the world of Game Vault.


gsaergsdffhsf wsghsfhhff:

As 3 Patti involves betting and understanding odds, it can help in improving financial literacy. Players learn to manage risks, make informed decisions click here, and understand the concept of probability.